Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1227 | Digital Health Online Platform Wiki | 0.50 |
| drug435 | BAT + Calcifediol Wiki | 0.50 |
| drug434 | BAT Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007592 | Joint Diseases NIH | 0.35 |
| D006467 | Hemophilia A NIH | 0.29 |
| D060085 | Coinfection NIH | 0.25 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001367 | Abnormal joint morphology HPO | 0.35 |
| HP:0003125 | Reduced factor VIII activity HPO | 0.29 |
| HP:0002090 | Pneumonia HPO | 0.03 |
Navigate: Correlations HPO
There are 4 clinical trials
Background. The recurrence of hemarthrosis in patients with congenital coagulopathies favors the development of a progressive, degenerative and intra-articular lesion (hemophilic arthropathy) that mainly affects the knees, ankles and elbows. Pain is one of the main clinical manifestations of hemophilic arthropathy. As a consequence of the COVID-19 pandemic, the Government of Spain, among others, established a total confinement for two months, in order to avoid contagion of the population Objective. To assess the effect of COVID-19 confinement on bleeding frequency, pain perception, and range of motion in patients with hemophilic arthropathy. Study design. Prospective observational study. Method. 27 patients with hemophilia A and B will be included in this study. Patients will be recruited from the Spanish Hemophilia Federation (Fishemo) specialized center for hemophilia patients. The dependent variables will be: the frequency of bleeding (through a self-report), the perception of pain (measured with the visual analog scale and a pressure algometer), the joint state (with the Hemophilia Joint Health Score), and the range of joint movement (measured with a goniometer). Two evaluations will be carried out: pre-treatment (carried out in the month of February, as a periodic evaluation) and post-treatment (at the end of the period of confinement in Spain). Expected results. The aim is to observe the sequelae caused by confinement and a sedentary lifestyle in patients with hemophilic arthropathy, through changes in joint status, pain and range of motion.
Description: The frequency of joint bleeding was assessed using a self-assessment log provided to patients at the beginning of confinement electronically. This registry included a monthly calendar where the patients included the date, symptoms and location of the hemarthrosis.
Measure: Change from baseline frequency of hemarthrosis after confinement period Time: Screening visit, within the first seven days after confinementDescription: Joint status was assessed with the Hemophilia Joint Health Score (HJHS) version 2.1. This tool, specific for hemophilia patients, evaluates joint deterioration in the ankle, knee and elbow joints. This scale measures 8 items: swelling, duration of swelling, atrophy and muscle strength, crepitus, mobility and joint pain. The scoring range for this additive scale is 0-20 points at each joint.
Measure: Change from baseline joint health after confinement period Time: Screening visit, within the first seven days after confinementDescription: Joint pain perception was measured with the visual analog scale. This scale has shown moderate reliability. The scoring range is from 0 to 10 points (from no pain to maximum perceived pain).
Measure: Change from baseline joint pain after confinement period Time: Screening visit, within the first seven days after confinementDescription: Range of motion was measured with a goniometer to assess flexion and extension of the elbow, knee, and ankle joints. This measuring instrument has shown good intra and inter-observer reliability in the joints evaluated. The measurement protocols described by Cleffken, Green and Gerhardt were used to measure mobility in the elbow, knee and ankle joints, respectively.
Measure: Change from baseline range of motion after confinement period Time: Screening visit, within the first seven days after confinementDescription: The pressure algometer measures the pressure, bilaterally, at which the patient perceives pressure pain on the evaluation point, as the pressure increases at a speed of approximately 50kPa / s. The unit of measurement is in Newton / cm2. The perception of joint pain in the elbow was measured on the lateral epicondyle, in the knee at a distance of 3 cm from the midpoint of the internal edge of the patella, and in the ankle it was measured in the ventral region of the lateral malleolus.
Measure: Change from baseline joint pain after confinement period Time: Screening visit, within the first seven days after confinementBy using recent data on hospital attendance and COVID-19 laboratory tests, available within two NHS trusts in Nottingham and Cardiff will enable the calculation of the risk of developing COVID-19 infection after attending an outpatient hospital appointment. This will assist in the restart planning when resuming face to face outpatient clinics.
Description: Information will be collected on patients age, gender, nature of appointment and whether patients received a positive or negative COVID-19 test.
Measure: A microbiological diagnosis of COVID infection. Time: 6 monthsMulticenter retrospective chart review of patients admitted to any of the four Methodist Health System hospitals
Description: Prevalence of subsequent and co-infections
Measure: Prevalence of subsequent and co-infections Time: Feb 2020 - April 2020Description: In-hospital mortality
Measure: In-hospital mortality Time: Feb 2020 - April 2020Description: Hospital length of stay (LOS)
Measure: Hospital length of stay (LOS) Time: Feb 2020 - April 2020This is a multi-center, observational study that will enroll 1) patients with severe COVID-19 who have agreed to undergo therapy with Seraph® 100 under the existing EUA; 2) patients (medical record data) that have been previously treated with the Seraph® 100 after the date of the EUA approval (17 April 2020), but before the date that the study is approved at the study site, and 3) a convenience sample of patients (medical record data) in a historical control group who were admitted to the ICU at participating sites with severe COVID-19 infection, meeting the EUA treatment criteria, but not treated with Seraph® 100 up to the time the PURIFY-OBS protocol is approved at the site
Description: list type of medication and length of medication for Blood pressure
Measure: Time spent on medications used to increase blood pressure Time: Measure from start of medication (day 0) to day 28 of studyDescription: Length of time on ventilator
Measure: Time spent on mechanical ventilation Time: From intubation date through extubation or day 28 of studyDescription: Length of time patient in the ICU
Measure: Time spent in the intensive care unit (ICU) Time: admission to ICU (day 0) through ICU discharge or up to day 28 of studyDescription: Length of time patient was hospitalized
Measure: Time spent in the hospital Time: from hospital admission (day 0) to discharge or up to day 28Description: length of time patient required dialysis
Measure: Time spent on dialysis Time: Start of dialysis treatment (day 0) to end of dialysis or up to day 28Description: survival
Measure: Mortality Time: From diagnosis of Covid (day 0) to date of death up to day 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports